Gyre Therapeutics: Under The Radar Biotech Has A Shot At MASH Approval, In Time [Seeking Alpha]
Gyre Therapeutics, Inc. (GYRE)
Company Research
Source: Seeking Alpha
Gyre focuses on developing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, with a successful drug, Etuary, approved for idiopathic pulmonary fibrosis. The company is conducting a Phase 2b study for hydronidone in patients with chronic hepatitis B-associated liver fibrosis and is targeting the MASH/NASH market in the US. With some good data behind it, it's not impossible that Gyre has an approvable drug on its hands, however I suspect the share price will fluctuate substantially and would advise maintaining a watching brief for now. Investment Overview Gyre Therapeutics ( NASDAQ: GYRE ) is an under the radar biotech company that achieved its listing on the Nasdaq in October last year via a merger between Catalyst Biosciences and GNI Group - according to a press release Catalyst received stockholder approval for all proposals necessary to complete the business combination at a special meeting of stockholders held on August 29, 2023. Catalyst
Show less
Read more
Impact Snapshot
Event Time:
GYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GYRE alerts
High impacting Gyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GYRE
News
- Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Public companies are Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) biggest owners and were rewarded after market cap rose by US$137m last week [Yahoo! Finance]Yahoo! Finance
- Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateGlobeNewswire
GYRE
Sec Filings
- 5/9/24 - Form 8-K
- 5/8/24 - Form 8-K
- 5/2/24 - Form 4
- GYRE's page on the SEC website